News 17.12.20

Glycostem and Ghent University announced a license agreement on NK cell therapy technology

We are glad to announce that Glycostem and Ghent University have signed a license agreement on NK cell therapy technology.

Read more
News 10.12.20

The future looks bright!

In the winter edition of Biotech NEWS & Life Sciences, Brigitte Drees talks about Pivot Park's future plans.

Read more
News 03.12.20

Digital kick-off of the policy framework economy 2030

On Wednesday, November 25, the province of North Brabant organized a digital kick-off of the policy framework economy 2030

Read more
News 01.12.20

Inprocess-LSP contributed successfully to Covid19 vaccine 

The NanoFlowSizer is now used for the measurement of the particle size

Read more
News 27.11.20

The Winners of the Venture Challenge 2020 are…

Pacing Cure and SLAM Orthopedic!

Read more
News 19.11.20

Pharming announces commitment to building a new downstream manufacturing facility at Pivot Park

At Pivot Park, Pharming will move into a new, sustainable, five-story building with a total floor space of approximately 4,000 m².

Read more
News 17.11.20

Lead Pharma enters into a Research Collaboration with Roche

Lead Pharma enters into a Research Collaboration and License Agreement with Roche.

Read more
News 11.11.20

PharmaCytics and Madam Therapeutics announce collaboration to develop a new class of oral anti-biotics

PharmaCytics and Madam Therapeutics announce collaboration to develop a new class of oral anti-biotics.

Read more
News 19.10.20

Press release Glycostem

12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.

Read more